REG - Ergomed plc - Proposed Board and Management Changes
RNS Number : 8274PErgomed plc13 February 2019PRESS RELEASE
FOR IMMEDIATE RELEASE
Proposed Board and Management Changes
Guildford, UK - 13 February 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.
Stuart will continue as a Board Director and Chief Financial Officer of Ergomed PLC until a replacement has been secured in order to ensure a smooth transition process. A search for his replacement is underway and the Company will provide an update on his successor in due course.
Dr Miroslav Reljanovic, Executive Chairman of Ergomed, said: "I would like to thank Stuart for his support and contribution to Ergomed. In the time he has been with us, he has made a positive impact on the business and has strengthened our finance and reporting capabilities. I look forward to continuing to work closely with him over the coming months whilst we select his successor. We wish Stuart every success in his new role."
- Ends -
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Miroslav Reljanovic (Executive Chairman)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDBOAGGUAWPUPBPGP
Recent news on Ergomed
See all newsREG - Ergomed plc - Cancellation of admission to trading of shares
AnnouncementREG - AIM Ergomed plc - Cancellation - Ergomed plc
AnnouncementREG - Takeover Panel - Disclosure Table
AnnouncementREG-Millennium Partners, L.P. Form 8.3 - Ergomed plc
AnnouncementREG - BlackRock Group Ergomed plc - Form 8.3 - Ergomed plc
Announcement